Every Form 4 that Pfizer Inc. (PFE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
PFIZER INC (symbol: PFE) is the issuer of record for a Form 4 filing submitted to the SEC. BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC (PFE) reported that Chairman & CEO Albert Bourla received an award of 22 Phantom Stock Units SSP on September 15, 2026. Each unit represents one phantom share of common stock and was valued at $27.55 per unit, increasing his directly held phantom stock units to 783,985. The units were granted under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash following his separation from service, with flexibility to transfer them into an alternative investment account at any time.
PFIZER INC (symbol: PFE) is the issuer of record for a Form 4 filing submitted to the SEC.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC (PFE) reported that Chairman & CEO Albert Bourla received an award of 22 Phantom Stock Units SSP on 2026-08-14. Each unit represents one phantom share of common stock and is valued at $26.79 per unit. Following this grant, Bourla holds 785,060 Phantom Stock Units, which are cash-settled under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan after his separation from service and may be reallocated into alternative investment accounts.
Pfizer Inc. Chairman & CEO Albert Bourla reported an open-market purchase of 38,000 shares of Pfizer common stock on 2026-08-12 at $26.34 per share. Following this transaction, he holds 429,173 shares directly and 6,382 shares indirectly through a Rule 16b-3 Plan.
Pfizer Inc officer Jennifer B. D'Amico, SVP & Controller, reported a sale of 3,278 shares of Common Stock on 2026-08-05 at $25.40 per share. Following this open market or private transaction, she directly held 28,611 Pfizer shares.
Pfizer Inc. director Ronald E. Blaylock purchased 39,231 shares of Common Stock on August 5, 2026 at $25.46 per share in an open market or private transaction. After this buy, he directly holds 66,938 shares and indirectly holds 4,750 shares by trust. The trade was not made under a Rule 10b5-1 plan.
Pfizer Inc. director Mortimer J. Buckley purchased 37,632 shares of common stock on August 5, 2026, in a transaction reported as a purchase in open market or private transaction at $25.52 per share. After this buy, he directly holds 37,632 Pfizer common shares.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24.0000 Phantom Stock Units SSP on July 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after separation from service, increasing his reported phantom unit balance to 786154.0000.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on July 15, 2026, at a reported transaction price of $24.82 per unit. Each unit represents one phantom share of common stock under Pfizer's Nonfunded Deferred Compensation and Supplemental Savings Plan.
The phantom units are settled in cash after Bourla's separation from service and may be transferred into an alternative investment account at any time. Following this grant, he holds 772,901 phantom stock units directly under the plan.
Pfizer Inc. Chairman & CEO Albert Bourla reported a compensation-related award of 84 Phantom Stock Units linked to Pfizer common stock on July 9, 2026. The units, valued at $24.25 per unit on the grant date, increase his directly held phantom stock balance to 772,938 units. These units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash following his separation from service.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman and CEO Albert Bourla received a routine compensation grant of 25 Phantom Stock Units under the company’s Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after his separation from service.
Following this award, Bourla holds a total of 772,979 phantom stock units. These units are a cash-settled, non-trading derivative tied to Pfizer’s common stock value and can be moved into an alternative investment account at his discretion, rather than being bought or sold on the open market.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley reported a compensation-related grant of 1,543.845 Phantom Stock Units tied to Pfizer common stock. The grant is priced at $24.29 per unit and represents deferred director compensation, including dividend equivalents.
According to the disclosure, these units will be settled in cash or common stock, at the director’s election, following his retirement from the Board of Directors. After this grant, Buckley now holds a total of 26,335.128 Phantom Stock Units directly. This filing reflects non‑market, derivative-based compensation rather than an open‑market share purchase or sale.
Pfizer Inc. director Joseph Echevarria received a grant of phantom stock units as deferred compensation. On this award date, he acquired 1,904.076 phantom stock units at a reference price of $24.2900 per unit, each unit representing one phantom share of common stock.
The units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or Pfizer common stock at his election after he retires from the Board. Following this grant, his balance in these phantom stock units increased to 165,631.508 units, indicating this is part of an ongoing deferred compensation program rather than an open-market trade.
NARAYEN SHANTANU reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Shantanu Narayen reported a new compensation grant linked to company stock. He received 2,058.460 Phantom Stock Units on June 26, 2026 at a reference value of $24.29 per unit, bringing his total Phantom Stock Unit balance to 200,879.336 units.
Each unit represents one phantom share of Pfizer common stock and reflects deferred director compensation, including dividend equivalents. According to the disclosure, these units will be settled in cash or common stock, at Narayen’s election, after he retires from Pfizer’s Board of Directors.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,852.614 Phantom Stock Units tied to Pfizer common stock. The units were awarded at a reference price of $24.2900 per unit and increase his phantom stock balance to 182,886.001 units.
According to the disclosure, these units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board of Directors. This is a compensation-related, non‑market transaction rather than an open‑market purchase or sale of Pfizer shares.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director James Quincey received a grant of 1,595.307 Phantom Stock Units linked to Pfizer common stock. The units were valued at $24.29 each and increase his deferred Phantom Stock Unit balance to 87,993.957 units following the transaction.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. These amounts are to be settled in cash or common stock, at the director's election, after he retires from Pfizer’s Board of Directors.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Cyrus Taraporevala received a compensation-related award of phantom stock units. On this date, he was granted 1,543.845 Phantom Stock Units linked to Pfizer common stock at a reference price of $24.29 per unit.
Each unit represents one phantom share of common stock and is part of deferred director compensation, including dividend equivalents. These units will be settled in cash or common stock, at the director’s election, after he retires from Pfizer’s Board. Following this award, his balance of phantom stock units stands at 36,941.287.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 23 phantom stock units tied to Pfizer common stock at a reference price of $26.00 per unit. This award increases his phantom stock unit balance to 772,772 units, which are cash-settled after his separation from service.
Pfizer Inc. reported that SVP & Controller Jennifer B. Damico executed an open-market sale of 2,000 shares of Pfizer common stock on June 9, 2026 at $25.70 per share. Following this transaction, she directly holds 31,397 Pfizer common shares.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC Chairman & CEO Albert Bourla reported a compensation-related grant of 23 Phantom Stock Units SSP linked to common stock. The units were awarded at a reference price of $26.18 per unit and increase his directly held phantom stock balance to 772,789 units.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after his separation from service and may be moved into an alternative investment account at any time, so they do not represent an open-market stock purchase or sale.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on common stock equivalents. Each unit represents one phantom share of Pfizer common stock, with the grant recorded at $25.33 per unit.
These units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash after Bourla’s separation from service and can be moved into an alternative investment account at any time. Following this grant, his reported phantom stock unit balance is 773,297 units.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 22 Phantom Stock Units linked to Pfizer common stock on April 30, 2026. Each unit represents one phantom share of common stock and is part of a deferred compensation arrangement, not an open-market stock purchase.
The units were awarded under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash after his separation from service. Following this grant, Bourla holds a total of 760,229 Phantom Stock Units directly under this plan.
Gottlieb Scott reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Scott Gottlieb received a new grant of phantom stock units as part of his board compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock at a reference value of $26.67 per unit, bringing his total phantom stock holdings to 57,001.814 units.
According to the footnotes, each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board of Directors, making this a non‑market, compensation-related transaction.
NORA JOHNSON SUZANNE M reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Suzanne M. Nora Johnson received a grant of 7,686.539 Phantom Stock Units on April 23, 2026. Each unit represents one phantom share of Pfizer common stock and was granted at a reference price of $26.67 per unit as deferred director compensation. Following this award, her balance in these units increased to 116,982.649. The units will be settled in cash or common stock, at her election, after she retires from the Board.
LITTMAN DAN R. reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Dan R. Littman received an award of 7,686.539 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of Pfizer common stock and is tied to a reference price of $26.67 per unit.
After this grant, Littman holds a total of 74,533.568 Phantom Stock Units. The units represent deferred director compensation under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at his election, after he retires from the Board.
BLAYLOCK RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Ronald E. Blaylock received a grant of 7,686.539 Phantom Stock Units linked to Pfizer common stock. The units, valued using a reference price of $26.67 per unit, increase his total phantom stock holdings to 84,012.660 units. Each unit represents one phantom share and was granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This award represents deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of phantom stock units as part of his deferred compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock, bringing his total phantom units to 24,391.124 held directly.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or Pfizer common stock, at the director’s election, after he retires from the Board of Directors.
Desmond-Hellmann Susan reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Susan Desmond-Hellmann received a grant of phantom stock units as part of her deferred board compensation. On this Form 4, she was awarded 7,686.539 phantom stock units, each linked to one share of Pfizer common stock. Following the award, she holds 45,635.605 phantom stock units in total. These units are granted under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and will be settled in cash or common stock, at her election, after she retires from the board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 7,686.539 Phantom Stock Units tied to common stock. The units were awarded as director compensation under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and bring his reported phantom unit balance to 161,084.684. Each unit represents one phantom share and will be settled in cash or common stock, at his election, after he retires from the board.
Pfizer Inc. director Shantanu Narayen received a grant of 7,686.539 Phantom Stock Units on common stock-equivalent terms. The award was made at a reference value of $26.67 per unit and is classified as a grant or award acquisition rather than an open-market purchase.
Following this grant, Narayen holds a total of 195,611.680 Phantom Stock Units directly. Each unit represents one phantom share of Pfizer common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation that will be settled in cash or common stock, at Narayen’s election, after his retirement from the Board.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC director James Quincey reported a compensation grant of phantom stock units tied to Pfizer common stock. He received 7,686.539 phantom stock units on the reported date at a reference value of $26.67 per unit.
Each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units reflect deferred director compensation and will be settled in cash or common stock, at Quincey’s election, after he retires from the Board. Following this award, his balance under this plan increased to 85,004.077 phantom stock units.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 7,686.539 Phantom Stock Units as deferred compensation. Each unit represents one phantom share of Pfizer common stock and was valued at $26.67 per unit for this award. After this grant, Smith holds 178,111.302 Phantom Stock Units directly. The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and represent deferred director compensation. According to the terms, these units will be settled in cash or Pfizer common stock, at Smith’s election, after he retires from the Board of Directors.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Cyrus Taraporevala received a grant of 7,686.539 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $26.67 per unit for this grant.
The award was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors as deferred director compensation. These units will be settled in cash or common stock, at the director’s election, after retirement from the Board of Directors. Following this grant, Taraporevala holds a total of 34,826.086 Phantom Stock Units directly.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
PFIZER INC Chairman & CEO Albert Bourla received a compensation-related grant of 22 Phantom Stock Units on common stock. The units were valued at $27.19 each and are part of Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan.
The phantom units are settled in cash after his separation from service and can be moved into an alternative investment account at any time. Following this grant, Bourla holds a total of 760,070 Phantom Stock Units directly under this plan.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of phantom stock units under a deferred compensation plan. On this Form 4, he acquired 911 phantom stock units linked to Pfizer common stock at a reference price of $27.11 per unit. Each unit represents one phantom share of common stock and is settled in cash, not actual shares, after his separation from service. Following this award, Bourla holds a total of 760,090 phantom stock units, reflecting deferred, cash-settled compensation rather than open-market share purchases or sales.
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 21 Phantom Stock Units on March 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is valued at $28.08 per unit.
These units are settled in cash after his separation from service and can be reallocated by him into another investment option at any time. Following this award, Bourla holds a total of 759,049 Phantom Stock Units directly.
Taraporevala Cyrus reported acquisition or exercise transactions in this Form 4 filing.
Pfizer director Cyrus Taraporevala received a grant of 1,386.834 phantom stock units tied to Pfizer common stock, valued at $27.04 per unit. After this award, his reported balance increased to 27,139.547 phantom stock units.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. These units will be settled in cash or common stock, at the director’s election, after he retires from the Board of Directors, making this a compensation and deferral event rather than an open-market trade.
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,664.2010 Phantom Stock Units linked to common stock as deferred board compensation. The units were valued at $27.0400 per unit and increase his phantom stock balance to 170,424.7630 units after the transaction.
Each unit represents one phantom share of Pfizer common stock and includes dividend equivalents. The award is part of deferred director compensation that will be settled in cash or common stock, at Smith’s election, after he retires from the Board of Directors, rather than an open-market purchase.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James Quincey received a grant of phantom stock units as deferred board compensation. On March 27, 2026, he was awarded 1,433.062 Phantom Stock Units, each linked to one share of Pfizer common stock and valued at $27.04 per unit. Following this award, his reported balance rose to 77,317.538 phantom units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board.
NARAYEN SHANTANU reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Shantanu Narayen received a compensation grant of 1,849.112 Phantom Stock Units tied to Pfizer common stock. The units were credited at a reference price of $27.04 per unit and increase his phantom stock balance to 187,925.141 units.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. According to the disclosure, these units will be settled in cash or Pfizer common stock, at the director's election, after he retires from the Board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 1,710.429 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $27.04 per unit on the grant date. After this award, his reported phantom unit balance increased to 153,398.145 units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or Pfizer common stock at his election after he retires from the Board of Directors.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of 1,386.834 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of common stock valued at $27.04. Following the award, Buckley holds 16,704.585 Phantom Stock Units, which will be settled in cash or stock after his retirement from the Board.
Pfizer Inc. reported that Chairman and CEO Albert Bourla acquired 1,630 phantom stock units linked to Pfizer common stock. The units were granted at a reference price of $26.58 per unit under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit tracks one share of common stock but is settled in cash after his separation from service rather than in actual shares. Following this grant, Bourla holds a total of 759,400 phantom stock units, providing cash-based exposure to Pfizer’s share value as part of his long-term compensation.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported equity compensation activity and related tax withholding. On March 3, she received grants of Pfizer common stock totaling 21,719 shares in the form of restricted stock units, which are subject to vesting requirements, and 22,638 stock appreciation rights that will be settled in common shares on the fifth anniversary of the grant date.
On March 4, 826 shares of common stock were withheld to cover tax obligations when restricted stock units (and related dividend equivalents) vested. After these transactions, she directly held 32,934 Pfizer common shares.
Pfizer Inc. reported that Chairman and CEO Albert Bourla received a grant of 708,666 stock appreciation rights on March 3, 2026. These rights were acquired as a grant or award, not through open-market purchases.
According to the disclosure, the stock appreciation rights are subject to vesting conditions and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this transaction, Bourla held a total of 708,666 stock appreciation rights directly.
BOSHOFF CHRISTOFFEL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. reported that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights on March 3, 2026. These derivative awards carry no purchase price and are part of his equity-based compensation.
The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, aligning the executive’s potential reward with long-term company performance.
Pfizer Inc. reported that Chief Financial Officer and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights on March 3, 2026. These awards were acquired at a stated price of $0.00 per right, reflecting an equity-based compensation grant rather than an open-market purchase.
The footnote explains that the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Following this grant, Denton’s reported direct derivative holdings in these rights total 216,537.
Pfizer Inc. Executive Vice President Douglas M. Lankler reported an acquisition of 194,883 stock appreciation rights on March 3, 2026. These derivative awards carry no exercise price and are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date, subject to vesting conditions.
MALIK AAMIR reported acquisition or exercise transactions in this Form 4 filing.
Pfizer executive vice president Aamir Malik received a grant of 194,883 stock appreciation rights on March 3, 2026. These derivative awards were granted at no cost and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant, subject to vesting requirements.
Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. Executive Vice President Andrew Baum reported an equity compensation grant in the form of 303,151 stock appreciation rights. These stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.